OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 15 of 19

16 Prescribing Obesity Medications Medications Used Off-Label for the Treatment of Obesity Drug Use/Class Common AEs Metformin Biguanide (T2DM, prediabetes) Diarrhea, nausea/vomiting (N/V), gas, fatigue, dyspepsia, B12; hypoglycemia with metabolic stress; lactic acidosis if renal function declines Pramlintide Amylin analog (adjunct to insulin in type 1 diabetes mellitus [T1DM]/ T2DM) Nausea, HA, anorexia, vomiting, abd pain, fatigue; hypoglycemia (with insulin) Topiramate Antiseizure/ migraine prevention Metabolic acidosis, cognitive slowing, paresthesia, somnolence, dizziness, fatigue, dysgeusia, abd pain Bupropion Antidepressant Dry mouth, HA, agitation, nausea, dizziness, constipation, tremor Lisdexamfetamine Stimulant (attention-def icit hyperactivity disorder [ADHD], binge-eating disorder [BED]) Anorexia, dry mouth, insomnia, upper abd pain, irritability Zonisamide Antiseizure Somnolence, dizziness, anorexia, nausea, HA, irritability, agitation, fatigue, concentration/memory issues

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026